Spirituality and healing.

abstract：:Rituximab shows high single-agent activity in both previously untreated and relapsed or refractory indolent non-Hodgkin's lymphoma. In combination with chemotherapy, rituximab has achieved response rates higher than 90% with long duration of remission in phase II studies. Therefore, randomized phase III studies have b...

journal_title：Seminars in oncology

authors： Hiddemann W,Dreyling M,Unterhalt M

更新日期：2003-02-01 00:00:00

abstract：:The epipodophyllotoxins, etoposide and teniposide, have been used in leukemias and malignant lymphomas for the past 15 years. Although etoposide has acquired a place in many first-line protocols for lymphomas and, more recently, for leukemias, the role of teniposide has remained limited. Teniposide is a more potent in...

journal_title：Seminars in oncology

authors： Sonneveld P

更新日期：1992-04-01 00:00:00

abstract：:Many patients with Hodgkin's and non-Hodgkin's lymphoma (NHL) can be cured today with combination chemotherapy and/or radiotherapy. However, for patients with suboptimal responses to initial therapy or for patients with refractory or relapsed disease, salvage therapy alone is usually inadequate to achieve long-term su...

journal_title：Seminars in oncology

authors： Laport GF,Williams SF

更新日期：1998-08-01 00:00:00

abstract：:This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

journal_title：Seminars in oncology

authors： Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

更新日期：2020-10-01 00:00:00

abstract：:A trial of combination chemotherapy using mitoxantrone-cyclophosphamide was started in 1983. Sixteen patients with widely metastatic cancer of the breast, including one man, received mitoxantrone, 10 mg/m2 intravenously (IV) over 30 minutes on day 1, followed by cyclophosphamide, 200 mg/m2 by mouth (PO) daily in divid...

journal_title：Seminars in oncology

authors： McDonald DB,Abu-Zahra H,Yoshida S,Binder H

更新日期：1984-09-01 00:00:00

abstract：:Improving local tumor control is a goal of modern radiotherapy that will directly impact a majority of cancer patients. Numerous attempts to develop radiosensitizing agents have, however, met with limited clinical success. Recent advances in gene therapeutic approaches have allowed researchers to combine gene therapy ...

journal_title：Seminars in oncology

authors： Advani SJ,Chmura SJ,Weichselbaum RR

更新日期：1997-12-01 00:00:00

abstract：:Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

journal_title：Seminars in oncology

authors： Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

更新日期：1993-10-01 00:00:00

abstract：:Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

journal_title：Seminars in oncology

authors： Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

更新日期：1992-04-01 00:00:00

abstract：:Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation "epigenetic drugs" are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availab...

journal_title：Seminars in oncology

authors： Covre A,Coral S,Di Giacomo AM,Taverna P,Azab M,Maio M

更新日期：2015-06-01 00:00:00

abstract：:For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer. It provided a response rate of 15% to 20%, with a median survival of approximately 1 year. In the past 5 years, remarkable progress has been made in colorectal cancer research with the approval of irinotecan ...

journal_title：Seminars in oncology

authors： Varadhachary GR,Hoff PM

更新日期：2005-12-01 00:00:00

abstract：:It is a truism that a better understanding of the biology of breast cancer should lead to improvements in diagnosis and therapy. Despite this, our significantly improved grasp of breast cancer biology has had little direct therapeutic impact to date. The technologies used to treat breast cancer (surgery, radiation the...

journal_title：Seminars in oncology

authors： Sledge GW Jr

更新日期：1996-02-01 00:00:00

abstract：:As a result of the increasing effectiveness of cancer screening and preventive interventions, ethical issues, as well as legal liabilities, are increasingly associated with cancer genetic testing. These issues include the possible "duty to warn" relatives of inherited cancer risk, the appropriateness of testing of chi...

journal_title：Seminars in oncology

authors： Offit K,Thom P

更新日期：2007-10-01 00:00:00

abstract：:The discovery of the HER2/neu proto-oncogene and its role in the pathogenesis of breast cancer tumors, and the development of the anti-HER2 monoclonal antibody, trastuzumab (Herceptin; Genentech, South San Francisco, CA), directed against the HER2 receptor represent major milestones in the research developments in bre...

journal_title：Seminars in oncology

authors： Slamon D,Pegram M

更新日期：2001-02-01 00:00:00

abstract：:Acquired immunodeficiency syndrome (AIDS)-related lymphomas consistently display a B-cell phenotype and are histogenetically related to germinal center (GC) or post-GC B cells in the overwhelming majority of cases. The pathogenesis of AIDS-related lymphoma is a multistep process involving factors provided by the host,...

journal_title：Seminars in oncology

authors： Gaidano G,Capello D,Carbone A

更新日期：2000-08-01 00:00:00

abstract：:The human tumor cloning system is an in vitro assay that has been used to predict response of patients' tumors to conventional antineoplastic agents as well as to biologic agents. In addition, the assay has been used to screen for antitumor activity of newly discovered cytotoxics and biologics. The purpose of the pres...

journal_title：Seminars in oncology

authors： Von Hoff DD

更新日期：1991-10-01 00:00:00

abstract：:Acute and chronic graft-versus-host disease (GvHD) remain major obstacles to successful allogeneic hematopoietic stem cell transplantation, contributing substantially to morbidity and non-relapse mortality. Better understanding of the immunopathophysiology of GvHD has identified a number of targets for intervention. A...

journal_title：Seminars in oncology

authors： Bruner RJ,Farag SS

更新日期：2003-08-01 00:00:00

abstract：:A primary goal of current clinical cancer research is the identification of prognostic tumor subtypes. It is increasingly clear that tumor growth depends on both internal tumor factors, and factors that are external to the tumor, such as microenvironment. We recently showed that parameter values alone are less importa...

journal_title：Seminars in oncology

authors： Pančoška P,Skála L,Nešetřil J,Carr BI

更新日期：2015-08-01 00:00:00

abstract：:Cardiovascular toxicity is one of the most feared complications of cancer treatment. Recent advances in oncologic therapies have resulted in improved cancer outcomes but also a new set of cardiovascular adverse effects. Common toxicities include left ventricular dysfunction/heart failure, hypertension, and myocardial ...

journal_title：Seminars in oncology

authors： Davis M,Witteles RM

更新日期：2013-04-01 00:00:00

abstract：:The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

journal_title：Seminars in oncology

authors： Klastersky J

更新日期：1985-03-01 00:00:00

abstract：:The development of targeted agents has brought new opportunities and extraordinary therapeutic challenges to cancer therapy. Several agents that inhibit epidermal growth factor receptor (HER1/EGFR) tyrosine kinase have been developed and are advanced in their clinical development. Preclinical and clinical data show th...

journal_title：Seminars in oncology

authors： Hortobagyi GN,Sauter G

更新日期：2003-06-01 00:00:00

abstract：:Gene therapy has now become a standard experimental approach for treating cancers that have failed conventional therapies. As the understanding of the molecular nature of carcinogenesis develops, new approaches are being taken to directly target tumor cells, thus bypassing the difficulties of killing cells that are re...

journal_title：Seminars in oncology

authors： Freeman SM,Whartenby KA,Freeman JL,Abboud CN,Marrogi AJ

更新日期：1996-02-01 00:00:00

abstract：:Solid malignancies often exhibit high interstitial fluid pressure (IFP), which causes poor uptake of anticancer drugs. While there are several mechanisms that regulate IFP in tumors, activation of platelet-derived growth factor receptor, which is expressed in various cell types within the tumor microenvironment, has b...

journal_title：Seminars in oncology

authors： Pietras K

更新日期：2004-04-01 00:00:00

abstract：:Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...

journal_title：Seminars in oncology

authors： Owen CE

更新日期：2016-06-01 00:00:00

abstract：:In patients with recurrent, previously irradiated head and neck cancer, the traditional therapy of palliative single- or multi-agent chemotherapy yields a 30% to 40% response rate with median survival durations of 8 to 10 months. However, long-term survival is rarely observed. Reirradiation with or without concurrent ...

journal_title：Seminars in oncology

authors： Chmura SJ,Milano MT,Haraf DJ

更新日期：2004-12-01 00:00:00

abstract：:90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

journal_title：Seminars in oncology

authors： Gordon LI

更新日期：2003-12-01 00:00:00

abstract：:Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

journal_title：Seminars in oncology

authors： Saad F,Eastham J

更新日期：2010-06-01 00:00:00

abstract：:Evidence published during several decades has shown that there is a group of epithelial ovarian tumors having histological and biological features between those of clearly benign and frankly malignant tumors. In 1963, FIGO accepted an intermediate group of ovarian carcinomas of low malignant potential. In 1973, WHO ad...

journal_title：Seminars in oncology

authors： Tropé C,Kaern J

更新日期：1998-06-01 00:00:00

abstract：:Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

journal_title：Seminars in oncology

authors： Halpern AC,Schuchter LM

更新日期：1997-02-01 00:00:00

abstract：:Initial phase I trials of intraperitoneal chemotherapy in ovarian cancer patients demonstrated that a pharmacologic advantage was achieved with the direct instillation of drugs into the peritoneal cavity. Recent trials have reported that approximately 30% of patients who have small-volume residual disease following in...

journal_title：Seminars in oncology

authors： Ozols R

更新日期：1985-09-01 00:00:00

abstract：:Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of treatment failure in patients with metastatic breast cancer. A phase I/II trial was initiated that combined the two most active drugs against breast cancer, doxorubicin and paclitaxel (Taxol; ...

journal_title：Seminars in oncology

authors： Rahman Z,Champlin R,Rondon G,Frye D,Valero V,Mehra R,Hortobagyi G

更新日期：1997-10-01 00:00:00